VASOTEC IV SOLUTION

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

ENALAPRILAT

Доступна с:

SANDOZ CANADA INCORPORATED

код АТС:

C09AA02

ИНН (Международная Имя):

ENALAPRIL

дозировка:

1.25MG

Фармацевтическая форма:

SOLUTION

состав:

ENALAPRILAT 1.25MG

Администрация маршрут:

INTRAVENOUS

Штук в упаковке:

2ML

Тип рецепта:

Prescription

Терапевтические области:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Обзор продуктов:

Active ingredient group (AIG) number: 0118001001; AHFS:

Статус Авторизация:

APPROVED

Дата Авторизация:

2008-04-03

Характеристики продукта

_ _
VASOTEC
®
IV
Page 1 of 30
PRODUCT MONOGRAPH
Pr
VASOTEC
® IV
ENALAPRILAT INJECTION
1.25 MG/ML IN 2 ML VIALS
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
Sandoz Canada Inc.
Date of Revision: September 20, 2013
145 Jules-Léger
Boucherville, QC, Canada
J4B 7K8
SUBMISSION CONTROL NO: 167061
_ _
VASOTEC
®
IV
Page 2 of 30
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................................
3
SUMMARY
PRODUCT
INFORMATION
..............................................................................................................
3
INDICATIONS
AND
CLINICAL
USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
3
WARNINGS
AND
PRECAUTIONS
........................................................................................................................
4
ADVERSE
REACTIONS
.........................................................................................................................................
7
DRUG
INTERACTIONS
........................................................................................................................................
13
DOSAGE
AND
ADMINISTRATION
....................................................................................................................
14
OVERDOSAGE
......................................................................................................................................................
15
ACTION
AND
CLINICAL
PHARMACOLOGY
...................................................................................................
15
STORAGE
AND
STABILITY
................................................................................................................................
17
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING
...........................